Hypofractionated radiotherapy in non small cell lung cancer: A review of the current literature

Reviews on Recent Clinical Trials

Volumn 5, Issue 2, 2010, Pages 103-111

  Beli, I ^a   Koukourakis, G ^a   Platoni, K ^a   Tolia, M ^a   Kelekis, N ^a   Kouvaris, J ^b   Syrigos, C ^c   Mystakidou, K ^b   Varveris, C ^d   Kouloulias, V ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

^d UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Hypofractionation; Lung cancer; Radiotherapy; Review

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; IRINOTECAN; MITOMYCIN; PACLITAXEL; VINDESINE;

ARTICLE; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DYSPHAGIA; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOBIOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PALLIATIVE CARE; RADIOTHERAPY DOSAGE;

EID: 77952826668     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488710791233608     Document Type: Article

References (62)

1. Ginsberg RJ, Vokes EE, Rosenzweig K. Non-small cell lung cancer: Epidemiology. In: DeVita VT, Ed. Principles and practice of oncology. 6th ed. Philadelphia: Lippincott Wil-liams & Wilkins 2001; pp. 941-959.
2. Simpson JR, Francis ME, Rao DV, et al. Palliative radiotherapy for inoperable carcinoma of the lung: Final report of a RTOG multiinstitutional trial. Int J Radiat Oncol Biol Phys 1985; 11: 751-8.
3. Salazar OM, Slawson RG, Strohl RA, et al. A prospective randomized trial comparing once-a-week vs daily radiation therapy for locally advanced, non-metastatic, lung cancer: a preliminary report. Int J Radiat Oncol Biol Phys 1986; 12: 779-87.
4. Teo P, Tai TH, Choy D, et al. A randomized study on palliative radiation therapy for inoperable non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1988; 14: 867-71.
5. Medical Research Council. Inoperable non-small cell lung cancer (NSCLC): A Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 1991; 63: 265-70.
6. Medical Research Council. A Medical Research Council randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small cell lung cancer and poor performance status. Br J Cancer 1992; 65: 934-41.
7. Slotman BJ, Njo KH, Karim AB, et al. Hypofractionated radiation therapy in unresectable stage III non-small cell lung cancer. Cancer 1993; 72: 1885-93.
8. Macbeth FR, Bolger JJ, Bailey AJ, et al. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Clin Oncol (R Coll Radiol) 1996; 8: 167-75.
9. Collins TM, Ash DV, Thorogood J, et al. An evaluation of the palliative role of radiotherapy in inoperable carcinoma of the bronchus. Clin Radiol 1988; 39: 284-6.
10. Stevens MJ, Begbie SD. Hypofractionated irradiation for inoperable non-small cell lung cancer. Aust Radiol 1995; 39: 265-70.
11. Rees GJ, Devrell CE, Newman HF, et al. Palliative radiotherapy for lung cancer: Two versus five fractions. Clin Oncol (R Coll Radiol) 1997; 9: 90-5.
12. Baldini EH. Palliative radiation therapy for non-small cell lung cancer. Hematol Oncol Clin North Am 1997; 11: 303-19.
13. Vyas RK, Suryanarayana U, Baboo HA, et al. Inoperable nonsmall cell lung cancer: palliative radiotherapy with two weekly fractions. Indian J Chest Dis Allied Sci 1998; 40: 171-4.
14. Lupattelli M, Maranzano E, Latini P, et al. Short-course palliative radiotherapy in non-small cell lung cancer: results of a prospective study. Am J Clin Oncol 2000; 23: 89-93.
15. Plataniotis GA, Kouvaris JR, Vlahos L, et al. A short radiotherapy course for locally advanced non-small cell lung cancer(NSCLC): Effective palliation and patients' convenience. Lung Cancer 2002; 35: 203-7.
16. Van Dyk J, Mah K, Keane TJ. Radiation-induced lung damage: dose-time-fractionation considerations. Radiother Oncol 1989; 14(1): 55-69.
17. Jin-Yue-Jin Kong FM, Chetty IJ, et al. Impact of fraction size on lung radiation toxicity: hypofractionation may be beneficial in dose escalation of radiotherapy for lung cancer. Int J Radiat Oncol Biol Phiys 2010; 76(3): 782-8.
18. Withers HR, Thames HD, Peters LJ. A new isoeffect curve for change in dose per fraction. Radiother Oncol 1983; 1: 187-91.
19. Wilson GD, Saunders MI, Dische S, et al. Direct comparison of bromodeoxyuridine and Ki-67 labeling indices in human tumors. Cell Prolif 1996; 29: 141.
20. Bentzen SM, Skoczylas JZ, Bernier J. Quantitative clinical radiobiology of early and late lung reactions. Int J Radiat Biol 2000; 76: 453-62.
21. Thames HD, Withers HR, Peters LJ, Fletcher G. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 1982; 8: 218-26.
22. Fowler JF. Fractionation and therapeutic gain. In: Steel GG, Adams GE, Peckham MJ, Eds. The biologicalbasis of radiotherapy. Amsterdam: Elsevier 1983.
23. Dubray B, Henry-Amar M, Meerwalt JH, et al. Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: the role of fractionation. Radiother Oncol 1995; 36(3): 211-7.
24. Shibamoto Y, Ike O, Mizuno H, Fukuse T, Hitomi S, Takahashi M. Proliferative activity and micronucleus frequency after radiation of lung cancer cells as assessed by the cytokinesis-block method and their relationship to clinical outcome. Clin Cancer Res 1998; 4(3): 677-82.
25. Tinnemans MM, Lenders MH, ten Velde GP, Blijham GH, Ramaekers FC, Schutte B. Prognostic value of cytokinetic parameters in lung cancer after in vivo bromodeoxyuridine labelling. Anticancer Res 1999; 19(1A): 531-4.
26. Feld RP, Abratt S, Graziano S, et al. Pretreatment minimal staging and prognostic factors for non-small cell lung cancer: an updated consensus report. Lung Cancer 1997; 17(Suppl 1): 3-10.
27. Abratt RP. Modelling tumour and treated lung volume influences in the irradiation of non-small cell lung cancer patients. Int J Radiat Oncol Biol Phys 2001; 49: 481-5.
28. Sibley GS. Radiotherapy for patients with medically inoperable Stage I nonsmall cell lung carcinoma. Cancer 1998; 82: 433-8.
29. Martel MK, Strawderman M, Hazuka MB, Turrisi AT, Fraass BA, Lichter AS. Volume and dose parameters for survival of non-small cell cancer. Radiother Oncol 1997; 44(1): 23-9.
30. Graham MV, Purdy JA, Harms W, Bosch W, Wasserman TH, Perez CA. Survival and prognostic factors of non-small cell lung cancer (NSCLC) patients treated with definitive three-dimensional (3D) radiation therapy. Int J Radiat Oncol Biol Phys 1998; 42(1 Suppl): 166.
31. Gauden S, Ramsay J, Tripcony L. The curative treatment by radiotherapy alone of Stage I nonsmall cell carcinoma of the lung. Chest 1995; 108: 1278-82.
32. Slotman BJ, Antonisse IE, Njo KH. Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer. Radiother Oncol 1996; 41: 41.
33. Noordijk EM, Clement E, Hermans J, Wever AMJ, Leer JWH. Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. Radiother Oncol 1988; 13: 83-9.
34. Uematsu M, Shioda A, Suda A, et al. Computed tomographyguided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001; 51: 666-70.
35. Nagata Y, Negoro Y, Aoki T, et al. Clinical outcomes of 3-D conformal hypofractionated single high dose radiotherapy for one or two lung tumors using a stereotactic body frame. Radiat Oncol 2002; 52: s1041-46.
36. Onimaru R, Shirato H, Shimizu S, et al. Tumor control and respiratiory function after stereotactic irradiation (STI) for primary and metastatic lung cancer. Radiat Oncol 2001; 51: S345.
37. Jeramic B, Casas F, Wang L, Perin B, Radiation therapy of early stage non small lung cancer Basel; Kager 2010; vol 42: pp. 87-93.
38. Brock J, Ashley S, Bedford J, Nioytsikou E, Brada M. Revew of hypofractionated small volume RT for early stage NSCLC. Clin Oncol (R Coll Radiol) 2008; 20(9): 666-76.
39. Holsti LR, Mattson K. A randomized study of split-course radiotherapy of lung cancer: long-term results. Int J Radiat Oncol Biol Phys 1980; 6: 977.
40. Lee R, Carr DT, Childs D. Comparison of split-course radiation therapy and continuous radiation therapy for unresectable bronchogenic carcinoma: 5-year results. Am J Roentgenol Radiat Ther Nucl Med 1976; 126: 116.
41. Routh A, Hickman BT, Khansur T. Report of a prospective trial*/split-course versus conventional radiotherapy in the treatment of non-small cell lung cancer. Radiat Med 1995; 13: 115.
42. Levitt SH, Bogrdus CR, Ladd G. Split-dose intensive radiation therapy in the treatment of advanced lung cancer: a randomized study. Radiology 1967; 88: 1159.
43. Perez CA, Stanley K, Grundy G, et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-small cell caricnoma of the lung: report of the Radiation Therapy Oncology Group. Cancer 1982; 50: 1091.
44. CHART Steering Committee, Saunders M, Dische S, Barrelt A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomised multicentre trial. Lancet 1997; 350(9072): 161-5.
45. Turrisi AT, III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 28(340): 265-71.
46. Mehta M, Scrimger R, Mackie R, Paliwal B, Chappell R, Fowler J. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001; 49(1): 230-3.
47. Graham MV, Pajak TE, Herskovic AM, Emami B, Perez CA. Phase I-II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results. Int J Radiat Oncol Biol Phys 1995; 31(4): 819-25.
48. Kiura K, Takigawa Y, Segawa H, et al. Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy for locally advanced non-smallcell-lung cancer. J Clin Oncol 2008 26: (suppl;abstr 7515).
49. Satouchi M, Yamamoto N, Chiba Y, et al. Randomized phase III study of mitomycin/vindesine/ cisplatin(MVP)versus weekly irinotecan/ carboplatin(IC)or weekly paclitaxel/carboplatin(PC)with concurrent thoracic radiotherapy(TRT)for unresectable stage IIInon-small cells lung cancer. J Clin oncol 2009; 27: (15s) (Suppl; abstr 7504).
50. Bradley J, Graham M, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Med Image Anal 2005; 61(2): 318-28.
51. Abratt RP, Shepherd LJ, Salton DG. Palliative radiation for stage 3 non-small cell lung cancer-a prospective study of two moderately high dose regimens. Lung Cancer 1995; 13: 137-43.
52. Bezjak A, Dixon P, Brundage M, et al. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTGSC.15). Cancer Treat Rev 2003; 29: 123-5.
53. Sundstrom S, Bremnes R, Aasebo U, et al. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-smallcell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol 2004; 22: 765-8.
54. Kramer GW, Wanders SL, Noordijk EM, et al. Results of the Dutch national study of the palliative effects of irradiation using two different treatment schemes for non-small-cell lung cancer. J Clin Oncol 2005; 23: 2962-70.
55. Senkus-Konefka E, Dziadziuszko R, Bednaruk-Mynski E, et al. A prospective, randomized study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC). Br J Cancer 2005; 92: 1038-45.
56. Donato V, Zurlo A, Bonfili P, et al. Hypofractionated radiation therapy for inoperable advanced non-small cell lung cancer. Tumori 1999; 85: 174-6.
57. Bhatt ML, Mohani BK, Kumar L, et al. Palliative treatment of advanced non small cell lung cancer with weekly fraction radiotherapy. Indian J Cancer 2000; 37: 148-52.
58. Cross CK, Berman S, Buswell L, et al. Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 58: 1098-105.
59. Rodrigues CI, Njo KH, Karim AB. Hypofractionated radiation therapy in the treatment of superior vena cava syndrome. Lung Cancer 1993; 10: 221-8.
60. Enami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic radiation. Int J Radiat Oncol Biol Phys 1991; 21: 109-22.
61. Pritoli L, Bindi M, Belezza A, et al. Unfavorable experience with hypofractionated radiotherapy in unresectable lung cancer. Tumori 1992; 78: 305.
62. Lester JF, MacBeth F, Toy E, Coles B. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev 2006; (4): CD002143.